HOME >> BIOLOGY >> NEWS
HHS awards $232 million in biodefense contracts for vaccine development

HHS Secretary Tommy G. Thompson today announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will administer the contracts.

"We are moving as quickly as possible to develop new vaccines to ensure that our nation is protected against an array of potential bioterror agents," Secretary Thompson said. "These new contracts are the next steps in our plans to build a robust stockpile of critical medical countermeasures and supplies, so we are even more prepared to respond to a biological attack or outbreak."

These awards respond to a key objective of the NIAID biodefense research agenda, which emphasizes the development of new and improved medical products against "Category A" agents--those considered by the Centers for Disease Control and Prevention to pose the greatest threat to national security.

The smallpox awards continue advanced development work that began in February 2003 on two modified vaccinia Ankara (MVA) vaccine candidates. These contracts will support larger scale manufacturing of the vaccines as well as further safety and effectiveness studies in animals and humans. The tularemia and plague awards will fund early-stage product development of the respective vaccines, which will include dosage formulation, pilot batch production and initial clinical assessment. All four contracts are for purchases of vaccine lots intended for research use. Any future purchases of additional vaccines for stockpiling in the event of an emergency will depend on the results of the research currently underway.

"In a short period of time, we have greatly expanded our partnerships with industry to spur the development of vaccines against the most deadly agents of bioterrorism," said Anthony S. Fauci, M.D.,
'"/>

Contact: NIAID Press Office
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
7-Oct-2004


Page: 1 2 3

Related biology news :

1. Argonne wins three R&D 100 awards for innovative technologies
2. ASBMB taps 8 scientists and 1 politician for top awards
3. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
4. US Department of Defense awards $1.6 million for implantable biochip research
5. 20 Kentucky firms share $1.9 million from state to match federal SBIR-STTR awards
6. The Cancer Genome Atlas awards funds for technology development
7. NIH awards nearly $21 million to fund cutting-edge research equipment
8. SNM presents awards on Capitol Hill
9. National awards for 2 University of York scientists
10. Burroughs Wellcome Fund awards $14M to support physician-scientists
11. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... , ... August 20, 2020 , ... ... Hassan Movahhed , a Clinical Operations executive with expertise in clinical trial ... joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has ...
(Date:8/5/2020)... ... 2020 , ... Regenative Labs has received approval from the Centers for Medicare ... the first Wharton’s jelly allografts to be assigned a Q code and be approved ... first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS ...
(Date:7/18/2020)... ... 16, 2020 , ... A study has been published in ... active noise control device to attenuate typical noises in a simulated neonatal intensive ... alarm sounds from patient monitors, ventilators and other bedside devices that would affect ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
(Date:7/31/2020)... ... 29, 2020 , ... R3 Stem Cell International is now offering patients the ... stem cells total, patients may choose which extremities they would like treated. , Several ... Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... radar transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and ... can drive one or two switches in a push-pull configuration; yielding fast fall ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and ... a strategic partnership whereby Catalent will provide support for the development, manufacturing, and ...
Breaking Biology Technology:
Cached News: